MedTrace Logo

Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT05533203 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-01-23

No results posted yet for this study

Summary

This phase I clinical trial is to evaluate the safety of Prodencel (an autologous dendritic cell therapeutic tumor vaccine.) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

Interventions

BIOLOGICAL

Prodencel; an autologous dendritic cell therapeutic tumor vaccine

Subcutaneous injection, each injection point should not exceed 1ml.

Sponsors & Collaborators

  • Shanghai Changhai Hospital,The First Affiliated Hospital of Naval Medical University

    collaborator UNKNOWN

  • Shanghai Humantech Biotechnology Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Linhui Wang, Ph.D. · Shanghai Changhai Hospital,The First Affiliated Hospital of Naval Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-08
Primary Completion
2023-08-30
Completion
2024-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05533203 on ClinicalTrials.gov